Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Clay-Based Pharmaceutical Formulations and Drug Delivery Systems
| Clay-Based Pharmaceutical Formulations and Drug Delivery Systems |
| Autore | Viseras César |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
| Descrizione fisica | 1 electronic resource (202 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
hydrochlorothiazide
cyclodextrins sepiolite nanoclay dissolution rate tablet electrospinning chitosan chondroitin sulfate scaffolds montmorillonite halloysite fibroblasts proliferation immune response glycosaminoglycans antimicrobial properties palygorskite spring water hydrogel fibroblast biocompatibility wound healing mesoporous clay Neusilin aeroperl liquisolid technique glyburide dissolution improvement hydrotalcite ketoprofen hybrid photostability hydrogel film bioadhesion heavy metal hazardous element element mobility clay minerals toxicity palygorksite proliferation Franz cell bioactive elements praziquantel drug organic solvents in vitro dissolution tests cytotoxicity targeted drug delivery halloysite nanotube osteosarcoma methotrexate surface modification |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557129803321 |
Viseras César
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Killing Cancer : Discovery and Selection of New Target Molecules
| Killing Cancer : Discovery and Selection of New Target Molecules |
| Autore | Kallunki Tuula |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (302 p.) |
| Soggetto topico |
Research & information: general
Biology, life sciences |
| Soggetto non controllato |
ferlin
myoferlin dysferlin otoferlin C2 domain plasma membrane sulconazole NF-κB IL-8 mammosphere breast cancer stem cells AF1Q MLLT11 WNT STAT esophageal cancer prognosis mTORC1 mTORC2 metabolism rapalogs mTOR inhibitors cancer metabolism mTOR in immunotherapy nutrient metabolism kinase inhibitors mTOR signaling MAPK kinase ERK1 ERK2 CD domain Rolled SCH772984 VRT-11E sevenmaker cancer therapy EMT lysosome lysosome-mediated invasion MZF1 phosphorylation PAK4 SUMOylation transcription factor zinc finger glucocorticoids 3D growth nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) epithelial-mesenchymal transition anoikis proliferation targeted cancer therapy disulfiram NPL4 replication stress DNA damage BRCA1 BRCA2 ATR pathway PDAC TCIRG1 ATP6V0a3 invasion migration matrix degradation pH-regulation autophagy multidrug resistance in cancer drug efflux pumps ATP-binding cassette transporter breast cancer resistance protein (BCRP) ABCG2 pyrazolo-pyrimidine derivative SCO-201 colorectal cancer immunotherapy inflammation microsatellite instability oncofetal chondroitin sulfate chondroitin sulfate cancer solid tumors target pediatric cancer VAR2 dexamethasone thyroid cancer microgravity space environment |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Killing Cancer |
| Record Nr. | UNINA-9910557648103321 |
|
Kallunki Tuula
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Looking Forward to the Future of Heparin: New Sources, Developments and Applications
| Looking Forward to the Future of Heparin: New Sources, Developments and Applications |
| Autore | Fareed Jawed |
| Pubbl/distr/stampa | MDPI - Multidisciplinary Digital Publishing Institute, 2018 |
| Descrizione fisica | 1 electronic resource (282 p.) |
| Soggetto non controllato |
alginate
edema Heparin Red solid lipid nanoparticles Fe3O4·DA-BSA/HA dermatan sulfate sulfated alginate porcine heparin theranostics low-molecular-weight heparin Arixtra® biomaterials hepcidin ovarian cancer iron oxide nanoparticles heparin-induced thrombocytopenia bone morphogenetic protein (BMP) hyaluronic acid (HA) crude heparin platelets resistance sclerostin LMWH gremlin low molecular weight heparin (LMWH) low molecular weight glycosaminoglycans human plasma single crystal X-ray structure iron homeostasis noggin super paramagnetic iron oxide nanoparticles (SPION) manufacturing methods paclitaxel (PTX) brain injury bovine heparin inflammation qNMR antithrombin reference standard quantitative NMR enoxaparin danaparoid sodium NMR GDNF orthogonal multi-analytical methods ternary complex heparan sulphate serglycin bovine serum albumin (BSA) HSQC recombinant expression heparin heparin oligosaccharides functional assay BMP antagonists intestinal lymphatic absorption size exclusion chromatography heparin coating diagnosis bioreactor anemia proteoglycan heparin process PCA chemometric fluorescent probe pharmacopeia affinity chromatography component quantitative analysis Fondaparinux sodium perylene diimide dyes thrombin inhibition extended physicochemical characterization cisplatin glycosaminoglycans TGF-? chondroitin sulfate dalteparin sequence and compositional investigations molecular weight magnetic resonance imaging (MRI) industrial LC-MS iduronic acid conformation heparan sulfate growth and differentiation factor (GDF) assay subarachnoid hemorrhage |
| ISBN | 3-03842-950-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Looking Forward to the Future of Heparin |
| Record Nr. | UNINA-9910346841803321 |
|
Fareed Jawed
|
||
| MDPI - Multidisciplinary Digital Publishing Institute, 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||